MCID: MYL006
MIFTS: 61

Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 53 29 55 15 72
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukemia Myelogenous 12
Leukemia, Myeloid 75

Classifications:



External Ids:

Disease Ontology 12 DOID:8692
ICD9CM 35 205 205.9
MeSH 44 D007951
NCIt 50 C3172
SNOMED-CT 68 37810007 94717009
ICD10 33 C92 C92.9 C92.90
UMLS 72 C0023470

Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid granulocytic leukemia, is related to cytogenetically normal acute myeloid leukemia and core binding factor acute myeloid leukemia. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Dopamine and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 75 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1184)
# Related Disease Score Top Affiliating Genes
1 cytogenetically normal acute myeloid leukemia 35.3 NPM1 FLT3 CEBPA
2 core binding factor acute myeloid leukemia 35.1 RUNX1 KIT FLT3 CEBPA CBFB
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.6 RUNX1 MYH11 KIT FLT3 ETV6 CBFB
4 acute myeloid leukemia with t(8;21)(q22;q22) translocation 34.5 RUNX1T1 RUNX1 KIT FLT3 CEBPA
5 acute myeloblastic leukemia with maturation 34.5 NPM1 KIT FLT3
6 acute promyelocytic leukemia 34.4 RUNX1 NPM1 FLT3 CEBPA
7 acute erythroid leukemia 34.3 GATA2 CEBPA
8 leukemia, chronic myeloid 33.7 RUNX1 NUP98 MECOM MCL1 KIT GATA2
9 acute myeloblastic leukemia without maturation 33.7 NPM1 FLT3
10 myeloid sarcoma 33.6 NPM1 KIT FLT3
11 8p11 myeloproliferative syndrome 33.4 RUNX1 KIT FLT3
12 myeloproliferative neoplasm 33.4 PTPN11 KIT ABL1
13 childhood leukemia 33.2 RUNX1 PTPN11 ETV6 ABL1
14 platelet disorder, familial, with associated myeloid malignancy 33.0 RUNX1 ETV6
15 leukemia 32.8 RUNX1T1 RUNX1 PTPN11 NPM1 MLF1 MCL1
16 acute leukemia 32.5 RUNX1 KIT FLT3 ETV6 CEBPA
17 leukemia, acute lymphoblastic 32.4 RUNX1 FLT3 ETV6 ABL1
18 leukemia, acute myeloid 32.3 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
19 myelodysplastic syndrome 32.2 U2AF1 RUNX1 PTPN11 NUP98 NPM1 MLF1
20 lymphocytic leukemia 32.1 RUNX1 PTPN11 MCL1 ETV6
21 leukemia, acute lymphoblastic 3 31.5 RUNX1 FLT3 ETV6 ABL1
22 chronic myelomonocytic leukemia 31.5 U2AF1 RUNX1 PTPN11 KIT FLT3 ETV6
23 precursor t-cell acute lymphoblastic leukemia 31.4 NUP98 FLT3 ETV6 ABL1
24 chronic eosinophilic leukemia 31.2 KIT FLT3 ABL1
25 aleukemic leukemia cutis 31.1 RUNX1 NPM1 MYH11 FLT3
26 aggressive systemic mastocytosis 30.5 PTPN11 KIT
27 bone marrow cancer 30.3 RUNX1 PTPN11 KIT FLT3 ETV6 ABL1
28 alk-positive anaplastic large cell lymphoma 30.2 NPM1 MCL1
29 hematologic cancer 30.1 RUNX1T1 RUNX1 PTPN11 NUP98 NPM1 MECOM
30 familial acute myeloid leukemia with mutated cebpa 12.8
31 atypical chronic myeloid leukemia 12.8
32 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 12.7
33 cebpa-associated familial acute myeloid leukemia 12.5
34 subacute myeloid leukemia 12.5
35 philadelphia-negative chronic myeloid leukemia 12.4
36 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.4
37 acute myeloid leukemia with t(9;11)(p22;q23) 12.4
38 acute myeloid leukemia with t(6;9)(p23;q34) 12.4
39 acute myeloid leukemia with minimal differentiation 12.4
40 acute myeloid leukemia with 11q23 abnormalities 12.4
41 unclassified acute myeloid leukemia 12.4
42 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.4
43 acute myeloid leukemia with recurrent genetic anomaly 12.3
44 acute myeloid leukemia and myelodysplastic syndromes related to radiation 12.3
45 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 12.3
46 acute myeloid leukemia with npm1 somatic mutations 12.3
47 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 12.3
48 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 12.3
49 megakaryocytic leukemia 12.2
50 erythroleukemia, familial 11.9

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
4 Increased shRNA abundance GR00327-A 9.35 CEBPA FLT3 MCL1 MYH11 PTPN11
5 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.1 GATA2 MCL1 MLF1 NUP98 RUNX1 RUNX1T1

MGI Mouse Phenotypes related to Myeloid Leukemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
2 cardiovascular system MP:0005385 10.33 ABL1 CBFB CEBPA ETV6 GATA2 KIT
3 growth/size/body region MP:0005378 10.32 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
4 embryo MP:0005380 10.29 ABL1 CBFB ETV6 GATA2 KIT MCL1
5 hematopoietic system MP:0005397 10.27 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
6 mortality/aging MP:0010768 10.22 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
7 immune system MP:0005387 10.21 ABL1 CBFB CEBPA ETV6 FLT3 KIT
8 endocrine/exocrine gland MP:0005379 10.19 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
9 integument MP:0010771 10.14 CBFB CEBPA ETV6 KIT MCL1 MECOM
10 digestive/alimentary MP:0005381 10.13 ABL1 CBFB CEBPA ETV6 KIT MYH11
11 liver/biliary system MP:0005370 10.02 ABL1 CBFB CEBPA GATA2 KIT MECOM
12 neoplasm MP:0002006 9.91 CBFB CEBPA ETV6 FLT3 KIT MECOM
13 no phenotypic analysis MP:0003012 9.76 CBFB CEBPA ETV6 FLT3 KIT NSD1
14 normal MP:0002873 9.7 ABL1 CBFB CEBPA ETV6 GATA2 KIT
15 respiratory system MP:0005388 9.23 ABL1 CBFB CEBPA KIT MECOM MYH11

Drugs & Therapeutics for Myeloid Leukemia

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 680)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Lenalidomide Approved Phase 4 191732-72-6 216326
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
9 Molgramostim Investigational Phase 4 99283-10-0
10
Aclarubicin Investigational Phase 4 57576-44-0 451415
11 Neurotransmitter Agents Phase 4
12 Dopamine Agents Phase 4
13 Psychotropic Drugs Phase 4
14 Antidepressive Agents Phase 4
15 Antidepressive Agents, Second-Generation Phase 4
16 Central Nervous System Stimulants Phase 4
17 Neurotransmitter Uptake Inhibitors Phase 4
18 Cholinergic Agents Phase 4
19 Nicotinic Agonists Phase 4
20 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
21 Dopamine Uptake Inhibitors Phase 4
22 Gemtuzumab Phase 4
23 Antiparasitic Agents Phase 4
24 Antiprotozoal Agents Phase 4
25 Vitamin D2 Phase 4
26 Ergocalciferols Phase 4
27 Hydroxycholecalciferols Phase 4
28 Imatinib Mesylate Phase 4 220127-57-1 123596
29 Tin Fluorides Phase 4
30 Angiogenesis Inhibitors Phase 4
31 Angiogenesis Modulating Agents Phase 4
32
Ondansetron Approved Phase 3 99614-02-5 4595
33
Fosaprepitant Approved Phase 3 172673-20-0 219090
34
Aprepitant Approved, Investigational Phase 3 170729-80-3 151165 6918365
35
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
36
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
37
Lenograstim Approved, Investigational Phase 3 135968-09-1
38
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
39 Orange Approved Phase 2, Phase 3
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
42
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
43
Morphine Approved, Investigational Phase 3 57-27-2 5288826
44
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
45
Ribavirin Approved Phase 3 36791-04-5 37542
46
Iodine Approved, Investigational Phase 3 7553-56-2 807
47
Ichthammol Approved Phase 3 8029-68-3
48
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
49
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965

Interventional clinical trials:

(show top 50) (show all 3296)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
2 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
3 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Unknown status NCT01243489 Phase 4
4 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
6 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
7 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
8 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
9 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
10 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
11 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
12 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
13 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
14 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
15 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
16 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
17 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
18 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
19 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
20 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
21 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
22 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
23 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
24 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
25 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
26 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
27 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
28 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
29 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
30 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
31 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
32 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
33 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
34 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
35 A Phase IV Study for Nilotinib in Patients With Imatinib-resistant or Intolerant Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase. Completed NCT01206088 Phase 4 nilotinib
36 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
37 A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
38 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
39 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
40 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
41 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
42 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
43 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415 Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
44 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
45 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
46 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
47 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
48 A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
49 A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF (REGISTERED)) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS Active, not recruiting NCT02228382 Phase 4 Bosutinib
50 A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID Active, not recruiting NCT02546674 Phase 4 Nilotinib

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


dasatinib
imatinib
ponatinib

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

MalaCards organs/tissues related to Myeloid Leukemia:

41
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

19
Myeloid Tissue

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 30745)
# Title Authors PMID Year
1
Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. 9 38
20042850 2010
2
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. 9 38
20445327 2010
3
Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation. 9 38
19917671 2010
4
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 9 38
20084277 2010
5
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 9 38
19935430 2010
6
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. 9 38
19880492 2010
7
Transforming growth-interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cells. 9 38
19699159 2009
8
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. 9 38
19734451 2009
9
[Supportive therapies for myeloid leukemia including blood transfusion and growth factors]. 9 38
19860196 2009
10
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. 9 38
19339050 2009
11
Decreased TLR4 gene expression in leukemic leukocyte populations. 9 38
19631641 2009
12
Retraction notice to "The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells" [Blood Cells Mol. Dis. 39 (2007) 307-315]. 9 38
19388154 2009
13
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. 9 38
19407318 2009
14
[Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. 9 38
19671288 2009
15
Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. 9 38
19429444 2009
16
[Apoptosis of human myeloid leukemia cell line HL-60 cells induced by siRNA targeting gene c-myc]. 9 38
19379561 2009
17
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. 9 38
19058874 2009
18
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. 9 38
19960054 2009
19
EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. 9 38
18815193 2008
20
AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. 9 38
18687517 2008
21
Expression profile of CREB knockdown in myeloid leukemia cells. 9 38
18801183 2008
22
DMNQ-S17 inhibits constitutive NF-kappaB activation leading to induction of apoptosis through the activation of caspase-3 in human myeloid leukemia U937 cells. 9 38
18718843 2008
23
PR1 vaccination in myeloid malignancies. 9 38
18767937 2008
24
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. 9 38
18059480 2008
25
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. 9 38
18569848 2008
26
[Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells]. 9 38
18822958 2008
27
Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines. 9 38
18455519 2008
28
TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. 9 38
18505930 2008
29
TGFbeta-mediated formation of pRb-E2F complexes in human myeloid leukemia cells. 9 38
18294958 2008
30
Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. 9 38
18483256 2008
31
Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1. 9 38
18345608 2008
32
Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. 9 38
18414055 2008
33
Evidence for CALM in directing VAMP2 trafficking. 9 38
18182011 2008
34
Targeted drug delivery via folate receptors. 9 38
18318652 2008
35
CREB is a critical regulator of normal hematopoiesis and leukemogenesis. 9 38
17975014 2008
36
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]. 9 38
18476539 2007
37
Increased responsiveness to TLR2 and TLR4 ligands during dimethylsulfoxide-induced neutrophil-like differentiation of HL-60 myeloid leukemia cells. 9 38
17664007 2007
38
[Expression and effect of neuropilin-1 in acute myeloid leukemic cells]. 9 38
18088455 2007
39
The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. 9 38
17644368 2007
40
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. 9 38
17917967 2007
41
Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. 9 38
17081606 2007
42
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. 9 38
17644747 2007
43
A TAF4-homology domain from the corepressor ETO is a docking platform for positive and negative regulators of transcription. 9 38
17572682 2007
44
Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. 9 38
17583492 2007
45
Evidence that the Pim1 kinase gene is a direct target of HOXA9. 9 38
17327400 2007
46
CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. 9 38
17431504 2007
47
Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. 9 38
17381798 2007
48
Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. 9 38
17604209 2007
49
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. 9 38
17213995 2007
50
Identification of novel nuclear localization signals of Drosophila myeloid leukemia factor. 9 38
18159124 2007

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
2 nucleoplasm GO:0005654 9.44 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
3 core-binding factor complex GO:0016513 9.16 RUNX1 CBFB

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 PTPN11 KIT FLT3 ABL1
2 cell differentiation GO:0030154 9.87 MLF1 MECOM MCL1 GATA2 FLT3 ETV6
3 cytokine-mediated signaling pathway GO:0019221 9.77 PTPN11 MCL1 KIT FLT3 CEBPA
4 cell fate determination GO:0001709 9.62 MCL1 GATA2
5 regulation of regulatory T cell differentiation GO:0045589 9.62 RUNX1 CBFB
6 regulation of keratinocyte differentiation GO:0045616 9.61 RUNX1 CBFB
7 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.61 RUNX1 CBFB
8 definitive hemopoiesis GO:0060216 9.6 GATA2 CBFB
9 negative regulation of programmed cell death GO:0043069 9.59 MECOM KIT
10 megakaryocyte development GO:0035855 9.58 PTPN11 KIT
11 regulation of bicellular tight junction assembly GO:2000810 9.58 RUNX1 CBFB
12 cell maturation GO:0048469 9.58 GATA2 CEBPA CBFB
13 regulation of response to DNA damage stimulus GO:2001020 9.56 MCL1 ABL1
14 hemopoiesis GO:0030097 9.56 RUNX1 KIT GATA2 FLT3
15 regulation of myeloid cell differentiation GO:0045637 9.55 RUNX1 CBFB
16 regulation of B cell receptor signaling pathway GO:0050855 9.54 RUNX1 CBFB
17 regulation of cytokine-mediated signaling pathway GO:0001959 9.51 RUNX1 CBFB
18 Bergmann glial cell differentiation GO:0060020 9.49 PTPN11 ABL1
19 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.46 RUNX1 CBFB
20 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.43 RUNX1 CBFB
21 hematopoietic stem cell proliferation GO:0071425 9.33 RUNX1 MECOM ETV6
22 myeloid progenitor cell differentiation GO:0002318 9.13 MLF1 KIT FLT3
23 regulation of hematopoietic stem cell differentiation GO:1902036 8.92 RUNX1 GATA2 CBFB ABL1
24 positive regulation of transcription, DNA-templated GO:0045893 10.03 RUNX1 NSD1 NPM1 MECOM CEBPA
25 regulation of transcription, DNA-templated GO:0006355 10.02 RUNX1T1 RUNX1 MLF1 GATA2 ETV6 CEBPA
26 negative regulation of transcription by RNA polymerase II GO:0000122 10 RUNX1 NSD1 GATA2 ETV6 CEBPA CBFB

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.81 RUNX1T1 RUNX1 MLF1 MECOM GATA2 ETV6
2 transcription coactivator activity GO:0003713 9.67 NUP98 NPM1 CEBPA CBFB
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 RUNX1 NSD1 GATA2 ETV6 CEBPA
4 protein domain specific binding GO:0019904 9.62 PTPN11 MLF1 ETV6 ABL1
5 protein binding GO:0005515 9.58 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
6 DNA-binding transcription factor activity GO:0003700 9.5 RUNX1T1 RUNX1 MECOM GATA2 ETV6 CEBPA

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....